Home › Compound Library › Mirabegron (Myrbetriq)

Mirabegron (Myrbetriq)

Urologicalprescriptionoral · inferred

Selective beta-3 adrenergic receptor agonist that relaxes detrusor smooth muscle during bladder filling, increasing bladder capacity. Alternative to antimuscarinics for overactive bladder with less cognitive/dry-mouth burden. 25-50 mg PO once daily (ER). Plasma half-life ~50h. Oral bioavailability ~29% at 25 mg; ~35% at 50 mg (nonlinear). CYP3A4 + CYP2D6 metabolism and moderate CYP2D6 inhibitor (interacts with metoprolol, desipramine). Notable hypertension signal — monitor BP.

Projected serum levels — 50 mg, once daily

Mirabegron (Myrbetriq)
Mirabegron (Myrbetriq) modeled serum levels, 50 mg once daily over 17 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 9 Day 13 Day 17 Time on a regular schedule ≈ steady state · day 4

Maintenance schedule: 50 mg once daily (oral).

Modeled steady state after ~4 days: peak ≈ 8.8 mg, trough ≈ 0.65 mg body load. Population-based estimate over 17 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Urological
Route modeled
Oral
Model confidence
inferred
Half-life
2.1 days
Common dose
50 mg
Suggested maximum
50 mg/day
Reference dose range
25–50 mg (single dose)
Suggested cadence
once daily
Validated against
50 mg oral — Cmax 0.091 mg/L at 3.5 h

Documented interactions

  • danger
    4-MMC (Mephedrone) + Mirabegron (Myrbetriq) CYP inhibition

    Mirabegron (Myrbetriq) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + Mirabegron (Myrbetriq) CYP inhibition

    Mirabegron (Myrbetriq) reversible_inhibitor of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~3.33x

  • danger
    Amphetamine (Adderall) + Mirabegron (Myrbetriq) CYP inhibition

    Mirabegron (Myrbetriq) reversible_inhibitor of CYP2D6 predicted to change Amphetamine (Adderall) AUC by ~2.11x

  • danger
    Atomoxetine (Strattera) + Mirabegron (Myrbetriq) CYP inhibition

    Mirabegron (Myrbetriq) reversible_inhibitor of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~2.68x

  • danger
    Carbamazepine (Tegretol) + Mirabegron (Myrbetriq) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Mirabegron (Myrbetriq) AUC by ~0.38x

  • danger
    Dextromethorphan (DXM) + Mirabegron (Myrbetriq) CYP inhibition

    Mirabegron (Myrbetriq) reversible_inhibitor of CYP2D6 predicted to change Dextromethorphan (DXM) AUC by ~2.47x

Serum checks 248 modeled interaction pairings for mirabegron (myrbetriq) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetic properties and safety of mirabegron, a selective β3-adrenoceptor agonist, after multiple oral dosing in healthy subjects Krauwinkel W et al. · European Journal of Drug Metabolism and Pharmacokinetics, 2012 DOI

    Multiple-dose PK study establishing mirabegron's ~50h terminal half-life, dose-proportional exposure, and steady-state in ~7 days.

  2. Mirabegron in overactive bladder: a randomised, double-blind, placebo-controlled, phase 3 study (SCORPIO) Chapple CR et al. · European Urology, 2014 DOI

    Pivotal SCORPIO phase 3 trial demonstrating mirabegron 50 mg QD reduces micturition frequency and incontinence episodes in OAB.

2 published studies referenced in the app, each with a plain-language summary.